Payment overview · 2025
General Payments
$849.47
41 reported records · 17 companies
Healthcare provider profile · identity verified
John David Harris, MD
Allopathic & Osteopathic Physicians|Family Medicine · RINGGOLD, GA · NPI 1871518860
Verified facts
What the public records show
CMS Open Payments records show John David Harris, MD received $849.47 in general payments during 2025 across 41 reported records.
PFIZER INC. accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $114.22 | 13.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $100.81 | 11.9% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.80 | 10.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.27 | 8.5% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $65.60 | 7.7% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $64.45 | 7.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $53.38 | 6.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $50.33 | 5.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.03 | 4.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.99 | 4.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.05 | 3.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.42 | 3.5% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.83 | 2.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.58 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.11 | 2.5% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $19.18 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.42 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $849.47 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $72.10 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $65.60 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $65.14 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $64.45 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.13 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $53.38 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $50.33 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $45.68 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.94 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.15 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $38.03 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.99 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.01 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.01 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.42 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| Iovera Normalized: iovera |
Device | Pacira Pharmaceuticals Incorporated | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| Zilretta Normalized: zilretta |
Drug | Pacira Pharmaceuticals Incorporated | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 35 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 72 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 13 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 127 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
127 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 421 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 366 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 363 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 351 | 101 |
| Lisinopril | Lisinopril | 307 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 302 | 97 |
| Losartan Potassium | Losartan Potassium | 290 | 88 |
| Gabapentin | Gabapentin | 286 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 66 |
| Omeprazole | Omeprazole | 205 | 61 |
| Meloxicam | Meloxicam | 203 | 58 |
| Tramadol Hcl | Tramadol Hcl | 184 | 42 |
| Metformin Hcl Er | Metformin Hcl | 181 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 48 |
| Furosemide | Furosemide | 157 | 45 |
| Trazodone Hcl | Trazodone Hcl | 156 | 48 |
| Montelukast Sodium | Montelukast Sodium | 152 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 36 |
| Carvedilol | Carvedilol | 130 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 127 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 125 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 121 | 41 |
| Potassium Chloride | Potassium Chloride | 115 | 36 |
| Allopurinol | Allopurinol | 104 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 102 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 32 |
| Simvastatin | Simvastatin | 97 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 43 |
| Celecoxib | Celecoxib | 92 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 29 |
| Ezetimibe | Ezetimibe | 88 | 22 |
| Metformin Hcl | Metformin Hcl | 83 | 32 |
| Famotidine | Famotidine | 82 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 24 |
| Spironolactone | Spironolactone | 80 | 25 |
| Sertraline Hcl | Sertraline Hcl | 77 | 29 |
| Jardiance | Empagliflozin | 76 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 21 |
| Eliquis | Apixaban | 72 | 20 |
| Mounjaro | Tirzepatide | 72 | 13 |
| Prednisone | Prednisone | 70 | 51 |
| Clonazepam | Clonazepam | 66 | suppressed |
| Lorazepam | Lorazepam | 66 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 16 |
| Xarelto | Rivaroxaban | 65 | 21 |
| Donepezil Hcl | Donepezil Hcl | 64 | 15 |
| Synthroid | Levothyroxine Sodium | 64 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 33 |
| Pregabalin | Pregabalin | 60 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 59 | 14 |
| Alprazolam | Alprazolam | 58 | 12 |
| Cefuroxime | Cefuroxime Axetil | 58 | 44 |
| Alendronate Sodium | Alendronate Sodium | 57 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 11 |
| Estradiol | Estradiol | 56 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 15 |
| Ozempic | Semaglutide | 54 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 51 | 29 |
| Benazepril Hcl | Benazepril Hcl | 50 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 14 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Diazepam | Diazepam | 44 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 16 |
| Atenolol | Atenolol | 43 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 12 |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Valsartan | Valsartan | 41 | 14 |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Linzess | Linaclotide | 39 | 13 |
| Methocarbamol | Methocarbamol | 39 | 11 |
| Ramipril | Ramipril | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 13 |
| Topiramate | Topiramate | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 17 |
| Meclizine Hcl | Meclizine Hcl | 37 | 19 |
| Temazepam | Temazepam | 37 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 36 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 35 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 19 |
| Azithromycin | Azithromycin | 33 | 29 |
| Buspirone Hcl | Buspirone Hcl | 33 | 12 |
| Finasteride | Finasteride | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 18 |
| Bumetanide | Bumetanide | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 29 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Praluent Pen | Alirocumab | 28 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 22 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Nystatin | Nystatin | 25 | 13 |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Baclofen | Baclofen | 23 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Indapamide | Indapamide | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | 11 |
| Digoxin | Digoxin | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | 14 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 14 |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Glimepiride | Glimepiride | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Telmisartan | Telmisartan | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Hyzaar | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $849.47 · 41 records | PFIZER INC. | ABRYSVO, ACCRUFER, AREXVY, Auvelity, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, GEMTESA, GVOKE HYPOPEN, Iovera, JARDIANCE, LEQVIO, MOUNJARO, NUCALA, NURTEC ODT, Ozempic, PREVNAR 20, PROLIA, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND, Zilretta | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error